Insider Selling: Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $239,505.90 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 11,845 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $20.22, for a total value of $239,505.90. Following the completion of the transaction, the insider owned 59,992 shares of the company’s stock, valued at approximately $1,213,038.24. The trade was a 16.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Filip Janku also recently made the following trade(s):

• On Wednesday, June 24th, Filip Janku sold 30,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $21.42, for a total value of $642,600.00.

Monte Rosa Therapeutics Stock Up 2.9%

Shares of NASDAQ GLUE opened at $22.28 on Friday. Monte Rosa Therapeutics, Inc. has a 52 week low of $4.12 and a 52 week high of $25.77. The business’s 50 day moving average price is $18.96 and its 200 day moving average price is $18.63. The firm has a market cap of $1.88 billion, a P/E ratio of -15.05 and a beta of 1.60.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The business had revenue of $4.21 million during the quarter, compared to analysts’ expectations of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. As a group, research analysts expect that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on GLUE. Guggenheim cut their price target on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. JPMorgan Chase & Co. boosted their price objective on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Wall Street Zen lowered Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, Wells Fargo & Company reduced their price target on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, March 18th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Monte Rosa Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $32.50.

Institutional Trading of Monte Rosa Therapeutics

Institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC purchased a new stake in shares of Monte Rosa Therapeutics in the first quarter valued at approximately $1,065,000. Goldman Sachs Group Inc. lifted its position in shares of Monte Rosa Therapeutics by 122.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company’s stock valued at $1,652,000 after buying an additional 196,238 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Monte Rosa Therapeutics in the 1st quarter valued at $76,000. Geode Capital Management LLC grew its stake in Monte Rosa Therapeutics by 12.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company’s stock valued at $5,071,000 after acquiring an additional 120,098 shares during the period. Finally, American Century Companies Inc. increased its holdings in Monte Rosa Therapeutics by 301.4% in the 2nd quarter. American Century Companies Inc. now owns 403,045 shares of the company’s stock worth $1,818,000 after acquiring an additional 302,639 shares in the last quarter. 79.96% of the stock is owned by institutional investors and hedge funds.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.